Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Sonoma Pharmaceuticals, Inc. SNOA

Healthcare — Drug Manufacturers Specialty & Generic

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
6.03
Revenue
21.92
Net Income
(2.26)
Free Cash Flow
(2.65)
Net Debt
(5.34)
Current Ratio
2.99
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
0.22
P/B ratio
0.75
Past 5Y EPS Growth
42.62%
This Y EPS Growth
28.47%
Next Y EPS Growth
65.22%
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2024 2025 2026 Q'26
Cash 3.13 5.37 2.40 5.34
Receivables 2.90 2.23 2.53 3.18
Inventory 2.72 2.92 3.65 3.79
Other — — — —
12.55 12.65 12.10 16.27
2024 2025 2026 Q'26
Payables 0.61 0.95 1.92 2.19
ST’ Debt 0.32 — — —
Other — — — —
3.72 4.10 4.83 5.45
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Jun Sep Dec Mar Year
’26 6.41 — — —
—
’26 4.02 5.60 4.35 5.56
19.53
’25 3.39 3.58 3.56 3.75
14.29
’24 3.43 2.73 3.14 3.44
12.74
’23 3.98 3.33 2.94 3.01
13.27
’22 3.68 3.74 2.90 2.30
12.63
’21 5.77 5.77 4.94 2.16
18.63
in millions of $

Operating Cash Flow

Jun Sep Dec Mar Year
’26 (0.65) — — —
—
’26 (2.01) (0.63) (0.76) (0.52)
(3.93)
’25 (0.91) 0.35 0.57 (0.09)
(0.09)
’24 (0.21) (1.23) (1.10) 0.15
(2.40)
’23 (1.53) (1.83) (0.35) (2.44)
(6.15)
’22 (1.22) (1.30) (0.33) (1.39)
(4.25)
’21 (2.29) (0.36) 0.75 (1.48)
(3.38)
in millions of $

Free Cash Flow

Jun Sep Dec Mar Year
’26 (0.65) — — —
—
’26 (2.12) (0.64) (0.81) (0.55)
(4.12)
’25 (0.92) 0.33 0.56 (0.14)
(0.17)
’24 (0.23) (1.23) (1.10) 0.17
(2.40)
’23 (1.56) (1.85) (0.38) (2.63)
(6.42)
’22 (1.27) (1.33) (0.33) (1.46)
(4.38)
’21 (2.34) (0.40) 0.67 (1.48)
(3.56)
in millions of $

EPS

Jun Sep Dec Mar Year
’26 (0.09) — — —
—
’26 (0.76) (0.32) (0.48) (0.33)
(1.89)
’25 (1.40) (0.59) (0.63) (0.48)
(2.79)
’24 (5.80) (5.80) (1.60) (1.40)
(10.60)
’23 (5.80) (6.60) (12.40) (6.20)
(30.40)
’22 (10.40) (0.80) (6.20) (19.00)
(38.40)
’21 10.80 1.20 (6.40) (35.20)
(39.40)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 20.00 2.40 2.44 1.75 0.85 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 97.00 53.60 9.40 6.92 3.89 — — —
High Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 11 9 10 8 9 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.15 1.47 1.27 1.79 2.17 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.63 13.27 12.74 14.29 19.53 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.62% 33.73% 37.26% 38.25% 37.97% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.42) (5.18) (5.03) (2.91) (3.42) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (42.90%) (39.06%) (39.51%) (20.35%) (17.51%) ‡‡‡ ‡‡‡ —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.09) (5.15) (4.83) (3.46) (3.17) ‡‡‡‡‡ ‡‡‡‡‡ —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.19 0.13 0.18 0.14 0.14 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 95.16 78.21 27.99 11.51 11.60 ‡‡‡‡‡ ‡‡‡‡‡ —
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.40) (30.40) (10.60) (2.79) (1.89) ‡‡‡‡‡ ‡‡‡‡ —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.01) (36.25) (5.27) (0.07) (2.34) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.03) (1.59) 0.00 (0.06) (0.11) ‡‡‡ ‡‡‡ —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (33.04) (37.84) (5.27) (0.14) (2.45) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 65.54 47.01 13.49 3.55 1.84 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13 0.17 0.46 1.24 1.68 ‡‡‡‡‡ ‡‡‡‡‡ —
Shares
‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.84 0.25 0.11 0.19 0.18 ‡‡‡ ‡‡‡ —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.22 0.42 0.22 0.62 1.16 ‡‡‡ ‡‡‡ —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.35 0.01 (0.10) (0.17) 0.07 ‡‡‡‡ ‡‡‡‡ —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.00) (0.02) 0.54 14.53 (0.34) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.25) (6.15) (2.40) (0.09) (3.93) ‡‡‡ ‡‡‡ —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.14) (0.27) 0.00 (0.08) (0.19) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (4.38) (6.42) (2.40) (0.17) (4.12) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.61 10.08 8.83 8.55 7.27 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.12 0.59 0.32 — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (6.28) (3.23) (2.80) (5.37) (2.40) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.70 7.98 6.14 4.41 3.10 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (30.07%) (29.37%) (31.22%) (24.32%) (22.96%) — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (152.17%) (60.13%) (88.18%) 0.00% (220.99%) — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (72.35%) (61.78%) (68.51%) (65.55%) (84.60%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Sonoma Pharmaceuticals (SNOA), a microcap medtech firm specializing in hypochlorous acid-based wound care products, has endured a dramatic fall from grace: revenues peaked at $18.6 million in 2021 with over 200 employees, but plunged post-pandemic, stabilizing around $13 million amid a 95% workforce slash to just 10 staff and reliance on outsourcing. Gross margins hover in the 30-40% range, respectable yet strained by production challenges, while chronic cash burn and cumulative losses exceeding $100 million since 2016 underscore operational fragility. The stock has cratered 99% from highs, perfectly tracking a 67-fold explosion in shares outstanding through relentless dilution.

Analyst forecasts dazzle with 42% revenue growth to $27 million by 2027, breakeven EPS, and 336% upside to consensus targets, fueled by partnerships like Clorox and European expansions. Yet, improving cash flows (near-breakeven in 2024) and negative net debt mask deeper woes: zero insider buying signals no conviction, ROE at -65%, and book value halved amid volatility. Historical patterns—COVID disruptions, failed trials, layoffs, and Nasdaq threats—reveal every revenue dip worsening losses without true leverage.

This turnaround tale tempts speculators, but contrarian history warns of a value trap in a competitive market dominated by giants, with risks from patent commoditization, regulatory hurdles, and supply chain pressures. Absent proven profitability and insider alignment, SNOA’s allure may prove illusory—read the full analysis for the data driving this cautious verdict.

Read full commentary →

Sonoma Pharmaceuticals, Inc. (SNOA) Latest News

News by impact score

Fine-tune

6 Aug

4 , 9:00 AM
Sonoma Pharmaceuticals achieved 141% U.S. revenue growth and 60% total revenue growth in fiscal Q1 while posting its first-ever positive adjusted EBITDA. Revenue surges and initial positive EBITDA indicate strengthened operations and investor appeal for Sonoma Pharmaceuticals.

30 Jun

4 , 9:00 AM
Sonoma Pharmaceuticals received FDA 510(k) clearance expanding indications and packaging options for Microdacyn Wound Irrigation Solution. FDA clearance broadens Microdacyn's commercial applications and market reach for Sonoma Pharmaceuticals.

16 Jun

3 , 4:15 PM
Sonoma Pharmaceuticals reported financial results for fiscal year and fourth quarter 2026. Quarterly and annual results typically produce moderate effects on valuation and sentiment.

24 Apr

4 ACCESS Newswire, 9:21 AM
Sonoma Pharmaceuticals priced a $4 million underwritten public offering of 1,454,546 shares of common stock (or pre-funded warrants) at $2.75 per share, expecting gross proceeds of $4 million before fees and expenses. $4 million capital raise funds operations and development but dilutes shareholders, significantly altering financial trajectory and market sentiment.

24 Mar

4 ACCESS Newswire, 8:30 AM
Sonoma Pharmaceuticals launches its advanced burn relief hydrogel in CVS and Walmart stores across the U.S. Retail launch in major chains like CVS and Walmart significantly boosts product accessibility and revenue potential.

18 Mar

4 ACCESS Newswire, 8:30 AM
Sonoma Pharmaceuticals launches new dermatology product line under Person & Covey's Aquanil brand targeting sensitive skin. New product line launch under established Aquanil brand expands dermatology offerings and targets sensitive skin market for revenue growth.

10 Feb

3 ACCESS Newswire, 4:10 PM
Sonoma Pharmaceuticals, Inc. (SNOA) reported its financial results for the third fiscal quarter of 2026, highlighting key metrics such as revenue, net income, and operational developments. The company continues to focus on its product pipeline and market expansion efforts, aiming to enhance its competitive position in the pharmaceutical industry. Management provided insights into future strategies and anticipated challenges, emphasizing a commitment to innovation and growth. Financial results and strategic insights indicate a moderate influence on the company's performance and market positioning.

28 Jan

3 ACCESS NewswireMT NewswiresMT NewswiresMT NewswiresPharma VoicePharmaceutical TechnologyMT NewswiresPharmaceutical Technology, 4:15 PM
Sonoma Pharmaceuticals, Inc. has announced the appointment of a new member to its Board of Directors and a new Senior Vice President of Regulatory, Quality, and Product Development. These additions are expected to enhance the company's leadership and strategic direction in regulatory and product development areas. The new appointments may positively influence product development and regulatory strategies, impacting the company's competitive positioning.

13 Nov

4 ACCESS Newswire, 8:30 AM
Sonoma Pharmaceuticals, Inc. has received the Seal of Acceptance from the National Rosacea Society for its product Reliefacyn Advanced, which is designed to provide relief for individuals suffering from rosacea. This recognition highlights the product's efficacy and safety, potentially enhancing its market presence and consumer trust. The Seal of Acceptance from a reputable organization is likely to significantly boost product credibility and sales potential in the rosacea treatment market.

6 Nov

3 , 4:01 PM
Sonoma Pharmaceuticals, Inc. (SNOA) will exhibit at MEDICA 2025, a prominent international trade fair for the medical sector, taking place in Düsseldorf. The event is expected to provide Sonoma with opportunities to showcase its innovative products and expand its market presence. Participation in MEDICA aligns with the company's strategy to enhance visibility and engage with potential partners and customers in the healthcare industry. Participation in MEDICA 2025 may enhance visibility and networking opportunities, positively influencing market sentiment and potential partnerships.

4 Nov

3 , 8:56 AM
Sonoma Pharmaceuticals, Inc. reported its financial results for the second fiscal quarter of 2026, highlighting key metrics such as revenue growth and operational developments. The company continues to focus on expanding its product offerings and market presence, aiming to enhance shareholder value. Management provided insights into future strategies and anticipated market trends that could influence performance. Moderate revenue growth and strategic developments may influence financial performance but are balanced by existing market conditions.

14 Oct

4 ACCESS Newswire, 8:30 AM
Sonoma Pharmaceuticals, Inc. has partnered with Medline Industries to introduce a new hypochlorous acid (HOCl) wound cleanser specifically designed for U.S. hospitals. This product aims to enhance wound care by providing an effective solution for cleansing and managing wounds, leveraging the antimicrobial properties of HOCl. The collaboration is expected to improve patient outcomes and streamline hospital procedures related to wound management. The launch of a new wound cleanser in collaboration with a major industry player like Medline is likely to significantly impact Sonoma's market position and financial performance.

7 Oct

4 ACCESS Newswire, 8:30 AM
Sonoma Pharmaceuticals, Inc. has expanded its market reach by registering a new FDA cosmetic product facility and listing a Microcyn-based cosmetic product under the Modernization of Cosmetics Regulation Act (MoCRA). This move is expected to enhance the company's product offerings and compliance with regulatory standards, potentially increasing its market presence in the cosmetic sector. The registration of a new facility and product listing under MoCRA represents a significant strategic move that could enhance market positioning and investor sentiment.

26 Aug

3 ACCESS NewswireACCESS NewswireACCESS NewswireGlobeNewswire, 8:30 AM
Sonoma Pharmaceuticals, Inc. has received the Seal of Recognition from the National Psoriasis Foundation for its product Reliefacyn Advanced, which is designed to provide relief for psoriasis symptoms. This recognition highlights the product's efficacy and aligns with the foundation's commitment to supporting effective treatments for psoriasis patients. Recognition from a reputable foundation may enhance product credibility and market perception, potentially influencing sales and investor sentiment.

19 Aug

4 , 8:50 AM
Sonoma Pharmaceuticals, Inc. (SNOA) is experiencing rapid momentum in its market performance, driven by recent developments and strategic initiatives. Despite this growth, the stock is still considered undervalued, presenting a potential buying opportunity for investors. Analysts highlight the company's innovative product pipeline and expanding market presence as key factors contributing to its positive outlook, suggesting that SNOA could outperform expectations in the near future. Significant strategic moves and product innovations are expected to alter the company's trajectory and investor sentiment.

14 Aug

4 GuruFocus.com, 1:55 PM
Sonoma Pharmaceuticals, Inc. (SNOA) experienced a dramatic 95% surge in stock price following the announcement of its products being available on Walmart and Amazon. This retail debut is expected to significantly enhance the company's market presence and accessibility to consumers, potentially driving sales growth. The increased visibility through these major retail platforms marks a pivotal moment for Sonoma, positioning it for greater consumer engagement and revenue opportunities. The retail launch on major platforms like Walmart and Amazon is a significant strategic move that could greatly enhance market reach and sales.

3 Associated Press Finance, 10:30 AM
Sonoma Pharmaceuticals, Inc. (SNOA) has been identified as one of the most active stocks in the market, reflecting heightened trading activity and interest among investors. This increased activity may be attributed to recent developments or market trends affecting the company. Investors are closely monitoring SNOA's performance as it navigates its operational landscape and potential growth opportunities. Increased trading activity suggests moderate investor interest, which may influence market sentiment and SNOA's financial performance.

13 Aug

3 ACCESS Newswire, 4:01 PM
Sonoma Pharmaceuticals, Inc. has launched a new diaper rash product that will be available at Walmart and other retail chains across the U.S. This product aims to address a common issue for parents and caregivers, expanding the company's product line and market reach. The launch of a new product in major retail chains is expected to moderately influence financial performance and market presence.

7 Aug

3 ACCESS Newswire, 4:15 PM
Sonoma Pharmaceuticals, Inc. (SNOA) reported its financial results for the first fiscal quarter of 2026, highlighting key metrics such as revenue, net income, and operational developments. The company continues to focus on its product pipeline and market expansion strategies, aiming to enhance its competitive position in the pharmaceutical sector. Management expressed optimism about future growth prospects and ongoing initiatives to drive innovation. The financial results indicate moderate performance that may influence investor sentiment and operational focus.

14 Jul

4 Zacks, 8:50 AM
Sonoma Pharmaceuticals, Inc. (SNOA) is highlighted as an attractively priced stock with fast-paced momentum, having increased 16.8% in the past four weeks and 57% over the last 12 weeks. The stock has a beta of 1.33, indicating higher volatility compared to the market, and a Momentum Score of A, suggesting a favorable entry point for investors. Additionally, SNOA has a Zacks Rank #2 (Buy) due to upward earnings estimate revisions. Despite its momentum, SNOA is trading at a low Price-to-Sales ratio of 0.42, indicating it is undervalued. This combination of factors positions SNOA for potential growth. SNOA's strong momentum, favorable earnings revisions, and attractive valuation suggest significant potential for future performance.

17 Jun

3 , 4:10 PM
Sonoma Pharmaceuticals, Inc. reported its financial results for the fiscal year and fourth quarter of 2025, highlighting key metrics such as revenue growth and operational achievements. The company continues to focus on expanding its product offerings and market presence, aiming to enhance shareholder value. Management provided insights into future strategies and anticipated market trends, indicating a positive outlook for the upcoming year. Revenue growth and operational achievements suggest a moderately noticeable influence on the company's financial performance.

22 Apr

4 ACCESS Newswire, 4:01 PM
Sonoma Pharmaceuticals, Inc. has registered its hypochlorous acid-based acne products with the UK's Medicines & Healthcare products Regulatory Agency (MHRA) for sale in over 1,200 stores of a leading pharmacy chain. The product line includes an acne toner and balancing serum, marketed under the retailer's brand. CEO Amy Trombly emphasized the products' safety and effectiveness, highlighting their all-natural formulation as an alternative to harsher ingredients. Sonoma aims to expand its distribution in Europe, leveraging its patented Microcyn technology. The registration and launch of new acne products in a major market like the UK represent a significant strategic move that could enhance Sonoma's market presence and financial performance.

27 Mar

4 Zacks, 8:50 AM
Sonoma Pharmaceuticals, Inc. (SNOA) is identified as a momentum stock trading at a bargain, with a recent four-week price change of 32.5% and a 12-week gain of 16.7%. The stock has a high beta of 1.56, indicating significant price movement relative to the market. SNOA holds a Momentum Score of A and a Zacks Rank #2 (Buy), supported by upward earnings estimate revisions. Despite its momentum, SNOA is trading at a low Price-to-Sales ratio of 0.36, suggesting it is undervalued. This combination of strong momentum and reasonable valuation positions SNOA favorably for potential investors. SNOA's strong momentum, favorable earnings revisions, and low valuation indicate significant potential for future performance.

11 Mar

4 , 8:50 AM
Sonoma Pharmaceuticals, Inc. (SNOA) is highlighted as a strong option for value investors due to its rapid growth and potential for future profitability. The company is recognized for its innovative product offerings and strategic positioning within the pharmaceutical market, which could lead to significant returns for investors. Analysts suggest that SNOA's current valuation presents an attractive entry point for those looking to capitalize on its growth trajectory. Sonoma Pharmaceuticals is poised for significant impact due to its innovative products and strategic market positioning.

10 Mar

4 ACCESS Newswire, 4:01 PM
Sonoma Pharmaceuticals, Inc. has received regulatory clearances from the U.K.'s Medicines & Healthcare Products Regulatory Agency (MHRA) for its manufacturing facility and five products, including hypochlorous acid-based wound care solutions. CEO Amy Trombly highlighted the significance of this registration for expanding into the U.K. market, which presents growth opportunities for the company's wound care and dermatology products. The U.K. regulatory clearances represent a significant strategic move that could enhance market presence and financial performance.

7 Feb

3 Simply Wall St., 5:07 AM
Sonoma Pharmaceuticals, Inc. (SNOA) is estimated to have a fair value of US$1.97, indicating it is currently 34% overvalued at a share price of US$2.65. The company's peers are trading at an average discount of 52%. A two-stage discounted cash flow (DCF) model was used to assess the intrinsic value, with a present value of future cash flows totaling US$2.6 million. Key assumptions include a discount rate of 5.9% and a terminal growth rate based on government bond yields. Despite being debt-free and having a sufficient cash runway, the stock's current valuation suggests it may be overpriced relative to its intrinsic value. The analysis indicates a moderate overvaluation of the stock, which could affect investor sentiment and financial performance.

3 , 5:05 AM
Sonoma Pharmaceuticals, Inc. (SNOA) reported its third quarter 2025 earnings, revealing that earnings per share (EPS) exceeded expectations, while revenues fell short of forecasts. The company continues to navigate challenges in revenue generation despite positive EPS results, indicating mixed performance in the market. Mixed earnings results suggest moderate influence on financial performance and market sentiment.

5 Feb

4 ACCESS Newswire, 4:05 PM
Sonoma Pharmaceuticals, Inc. reported a 14% increase in revenues for Q3 2025, totaling $3.6 million, and a 13% increase year-to-date, reaching $10.5 million. The company achieved positive cash flow from operations and reduced its year-to-date net loss by $1.1 million. Despite a 29% decline in U.S. sales, Sonoma expanded its distribution network through partnerships with Medline Industries and WellSpring Pharmaceutical, and received new regulatory approvals for its products. Operating expenses remained flat, while gross profit margins decreased due to increased manufacturing costs related to regulatory compliance. New partnerships and regulatory approvals are expected to significantly enhance sales and market positioning.

5 Dec

4 ACCESSWIRE, 8:30 AM
Sonoma Pharmaceuticals, Inc. successfully transitions four products to new EU MDR requirements for Class IIb medical devices. Transition to new EU MDR requirements for key products is a significant strategic move that demonstrates compliance and expands market opportunities.

27 Nov

4 Zacks, 8:50 AM
Sonoma Pharmaceuticals, Inc. (SNOA) is identified as a bargain stock with fast-paced momentum, favorable valuation, and positive earnings estimate revisions. The article highlights significant potential impact on SNOA's future and market performance through fast-paced momentum, favorable valuation, and positive earnings estimate revisions.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us